Category: Markets
Published: 2026-07-16T13:18:38.000Z
Arbutus Biopharma (ABUS) and Genevant Sciences have initiated three international lawsuits against Pfizer and BioNTech, alleging patent infringements related to their COVID-19 vaccine's lipid nanoparticle technology. This action follows a prior U.S. dispute and a $178 million settlement with Moderna. Despite strong financial stability (10/10), Arbutus has low profitability and growth scores, and its P/E ratio of 5.5 suggests it may be undervalued.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.